{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:15:12Z","timestamp":1771298112344,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T00:00:00Z","timestamp":1461974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T00:00:00Z","timestamp":1461974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009741","name":"National Blood Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000019","name":"National Hemophilia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000019","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cures within Reach"},{"DOI":"10.13039\/100006021","name":"US Immunodeficiency Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["N01-A1-30070"],"award-info":[{"award-number":["N01-A1-30070"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R56A1091791"],"award-info":[{"award-number":["R56A1091791"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21A1099301"],"award-info":[{"award-number":["R21A1099301"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foerderer-Murray Award"},{"name":"Partnership for Cures Patient Impact Initiative"},{"name":"Barbara Brodsky"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40272-016-0175-3","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T11:07:50Z","timestamp":1462014470000},"page":"261-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children"],"prefix":"10.1007","volume":"18","author":[{"given":"Lindsey A.","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,30]]},"reference":[{"key":"175_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/82712","volume":"1","author":"RM Siegel","year":"2000","unstructured":"Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol. 2000;1:469\u201374.","journal-title":"Nat Immunol"},{"key":"175_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/0092-8674(95)90013-6","volume":"81","author":"GH Fisher","year":"1995","unstructured":"Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935\u201346.","journal-title":"Cell"},{"key":"175_CR3","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1126\/science.7539157","volume":"268","author":"F Rieux-Laucat","year":"1995","unstructured":"Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fisher A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347\u20139.","journal-title":"Science"},{"key":"175_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1172\/JCI115867","volume":"90","author":"MC Sneller","year":"1992","unstructured":"Sneller MC, Straus SE, Jaffe ES, Fleisher TA, Stetler-Stevenson M, Strober W. A novel lymphoproliferative\/autoimmune syndrome resembling murine lpr\/gld disease. J Clin Invest. 1992;90:334\u201341.","journal-title":"J Clin Invest."},{"key":"175_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/356314a0","volume":"356","author":"R Watanabe-Fukunaga","year":"1992","unstructured":"Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314\u20137.","journal-title":"Nature"},{"key":"175_CR6","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1182\/blood-2010-04-280347","volume":"116","author":"JB Oliveira","year":"2010","unstructured":"Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, Rieux-Laucat F, Siegel RM, Su HC, Teachey DT. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116:e35\u201340.","journal-title":"Blood"},{"key":"175_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood-2014-03-564286","volume":"124","author":"A Rensing-Ehl","year":"2014","unstructured":"Rensing-Ehl A, V\u00f6lkl S, Speckmann C, Lorenz MR, Ritter J, Janda A, et al. Abnormally differentiated CD4+ or CD8+ T\u00a0cells with phenotypic and genetic features of double negative T\u00a0cells in human Fas deficiency. Blood. 2014;124:851\u201360.","journal-title":"Blood"},{"key":"175_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cellimm.2013.06.011","volume":"284","author":"IV Grishkan","year":"2013","unstructured":"Grishkan IV, Ntranos A, Calabresi PA, Gocke AR. Helper T\u00a0cells down-regulate CD4 expression upon chronic stimulation giving rise to double-negative T\u00a0cells. Cell Immunol. 2013;284:68\u201374.","journal-title":"Cell Immunol"},{"key":"175_CR9","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1182\/blood-2011-07-325217","volume":"118","author":"VK Rao","year":"2011","unstructured":"Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood. 2011;118:5741\u201351.","journal-title":"Blood"},{"key":"175_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MOP.0b013e32834ea739","volume":"24","author":"DT Teachey","year":"2012","unstructured":"Teachey DT. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr. 2012;24:1\u20138.","journal-title":"Curr Opin Pediatr"},{"key":"175_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2141.2009.07991.x","volume":"148","author":"DT Teachey","year":"2010","unstructured":"Teachey DT, Seif AE, Grupp SA. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol. 2010;148:205\u201316.","journal-title":"Br J Haematol"},{"key":"175_CR12","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.4049\/jimmunol.1100021","volume":"186","author":"HS Kuehn","year":"2011","unstructured":"Kuehn HS, Caminha I, Niemela JE, Rao VK, Davis J, Fleisher TA, Oliveira JB. FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome. J Immunol. 2011;186:6035\u201343.","journal-title":"J Immunol."},{"key":"175_CR13","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1182\/blood-2008-09-179630","volume":"113","author":"A Magerus-Chatinet","year":"2009","unstructured":"Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, Neven B, Schaffner C, Ducrot N, et al. FAS-L, IL-10, and double-negative CD4\u2212 CD8\u2212 TCR alpha\/beta+ T\u00a0cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood. 2009;113:3027\u201330.","journal-title":"Blood"},{"key":"175_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMoa040036","volume":"351","author":"E Holzelova","year":"2004","unstructured":"Holzelova E, Vonarbourg C, Stolzenberg MC, Arkwright PD, Selz F, Prieur AM, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med. 2004;351:1409\u201318.","journal-title":"N Engl J Med"},{"key":"175_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1172\/JCI43752","volume":"121","author":"A Magerus-Chatinet","year":"2011","unstructured":"Magerus-Chatinet A, Neven B, Stolzenberg MC, Daussy C, Arkwright PD, Lanzarotti N, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest. 2011;121:106\u201312.","journal-title":"J Clin Invest."},{"key":"175_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(96)02293-3","volume":"348","author":"F Le Deist","year":"1996","unstructured":"Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N, et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet. 1996;348:719\u201323.","journal-title":"Lancet"},{"key":"175_CR17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood.V89.4.1341","volume":"89","author":"MC Sneller","year":"1997","unstructured":"Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, et al. Clincial, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89:1341\u20138.","journal-title":"Blood"},{"key":"175_CR18","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1182\/blood-2013-10-535393","volume":"123","author":"S Price","year":"2014","unstructured":"Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, Perkins K, Hornung RL, Folio L, Rosenberg PS, Puck JM, Hsu AP, Lo B, Pittaluga S, Jaffe ES, Fleisher TA, Rao VK, Lenardo MJ. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014;123:1989\u201399.","journal-title":"Blood"},{"key":"175_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/10428190310001593166","volume":"45","author":"S Poppema","year":"2004","unstructured":"Poppema S, Maggio E, van den Berg A. Development of lymphoma in autoimmune lymphoproliferative syndrome (ALPS) and its relationship to Fas gene mutations. Leuk Lymphoma. 2004;45:423\u201331.","journal-title":"Leuk Lymphoma"},{"key":"175_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1006\/clim.2002.5225","volume":"104","author":"JJ Bleesing","year":"2002","unstructured":"Bleesing JJ, Brown MR, Novicio C, Guarraia D, Dale JK, Stauss SE, et al. A composite picture of TcR alpha\/beta(+) CD4(\u2212)CD8(\u2212) T\u00a0cells (alpha\/beta-DNTCs) in humans with auto-immune lymphoproliferative syndrome. Clin Immunol. 2002;104:21\u201330.","journal-title":"Clin Immunol."},{"key":"175_CR21","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1126\/science.288.5475.2354","volume":"288","author":"RM Siegel","year":"2000","unstructured":"Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 2000;288:2354\u20137.","journal-title":"Science"},{"issue":"8","key":"175_CR22","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1073\/pnas.96.8.4552","volume":"96","author":"DA Martin","year":"1999","unstructured":"Martin DA, Zheng L, Siegel RM, Huang B, Fisher GH, Wang J, et al. Defective CD95\/APO-1\/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type\u00a0Ia. Proc Natl Acad Sci. 1999;96(8):4552\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"175_CR23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jaci.2009.12.983","volume":"125","author":"I Caminha","year":"2010","unstructured":"Caminha I, Fleisher TA, Hornung RL, Dale JK, Niemela JE, Price S, et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2010;125:946\u20139.","journal-title":"J Allergy Clin Immunol."},{"key":"175_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaci.2015.09.025","volume":"137","author":"L G\u00e1mez-D\u00edaz","year":"2016","unstructured":"G\u00e1mez-D\u00edaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M, et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol. 2016;137:223\u201330.","journal-title":"J Allergy Clin Immunol."},{"key":"175_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10875-015-0224-7","volume":"36","author":"OK Alkhairy","year":"2016","unstructured":"Alkhairy OK, Abolhassani H, Rezaei N, Fang M, Andersen KK, Chavoshzadeh Z, et al. Spectrum of phenotypes associated with mutations in LRBA. J Clin Immunol. 2016;36:33\u201345.","journal-title":"J Clin Immunol"},{"issue":"4","key":"175_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2014-09-602763","volume":"125","author":"JD Milner","year":"2015","unstructured":"Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125(4):591\u20139.","journal-title":"Blood"},{"issue":"115","key":"175_CR27","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1182\/blood-2009-08-239525","volume":"18","author":"AE Seif","year":"2010","unstructured":"Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood. 2010;18(115):2142\u20135.","journal-title":"Blood"},{"key":"175_CR28","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood-2004-09-3542","volume":"105","author":"DT Teachey","year":"2005","unstructured":"Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH, McMann JM, Sullivan KE, Travis SF, Grupp SA. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105:2443\u20138.","journal-title":"Blood"},{"key":"175_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3324\/haematol.2010.036053","volume":"96","author":"N Aladjidi","year":"2011","unstructured":"Aladjidi N, Leverger G, Leblanc T, Picat MQ, Michel G, Bertrand Y, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96:655\u201363.","journal-title":"Haematologica"},{"key":"175_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.clim.2007.08.010","volume":"125","author":"S Savasan","year":"2007","unstructured":"Savasan S, Warrier I, Buck S, Kaplan J, Ravindranath Y. Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans\u2019 syndrome. Clin Immunol. 2007;125:224\u20139.","journal-title":"Clin Immunol."},{"key":"175_CR31","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/01.pas.0000157997.61177.08","volume":"29","author":"I Maric","year":"2005","unstructured":"Maric I, Pittaluga S, Dale JK, Niemela JE, Delsol G, Diment J, et al. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am J Surg Pathol. 2005;29:903\u201311.","journal-title":"Am J Surg Pathol"},{"key":"175_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature01063","volume":"419","author":"HJ Chun","year":"2002","unstructured":"Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419:395\u20139.","journal-title":"Nature"},{"issue":"4","key":"175_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s10875-015-0150-8","volume":"35","author":"J Niemela","year":"2015","unstructured":"Niemela J, Kuehn HS, Kelly C, Zhang M, Davies J, Melendez J, et al. Caspase-8 deficiency presenting as late-onset multi-organ lymphocytic infiltration with granulomas in two adult siblings. J Clin Immunol. 2015;35(4):348\u201355.","journal-title":"J Clin Immunol"},{"key":"175_CR34","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1182\/blood-2010-07-295501","volume":"117","author":"JE Niemela","year":"2010","unstructured":"Niemela JE, Lu L, Fleisher TA, Davis J, Caminha I, Natter M, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood. 2010;117:2883\u20136.","journal-title":"Blood"},{"key":"175_CR35","doi-asserted-by":"publisher","first-page":"8953","DOI":"10.1073\/pnas.0702975104","volume":"104","author":"JB Oliveira","year":"2007","unstructured":"Oliveira JB, Bidere N, Niemela JE, Zheng L, Sakai K, Nix CP, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci. 2007;104:8953\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"175_CR36","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1182\/blood-2010-08-301515","volume":"117","author":"M Takagi","year":"2010","unstructured":"Takagi M, Shinoda K, Piao J, Mitsuiki N, Matsuda K, Muramatsu H, et al. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood. 2010;117:2887\u201390.","journal-title":"Blood"},{"key":"175_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","volume":"15","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T\u00a0cell senescence and human immunodeficiency. Nat Immunol. 2014;15:88\u201397.","journal-title":"Nat Immunol"},{"issue":"6160","key":"175_CR38","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","volume":"342","author":"I Angulo","year":"2013","unstructured":"Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase\u00a0\u03b4 gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866\u201371.","journal-title":"Science"},{"key":"175_CR39","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1172\/JCI75746","volume":"124","author":"MC Deau","year":"2014","unstructured":"Deau MC, Heurtier L, Frange P, Suarez F, Bole-Feysot C, Nitschke P, Cavazzana M, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014;124:3923\u20138.","journal-title":"J Clin Invest."},{"key":"175_CR40","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1084\/jem.20141759","volume":"211","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Zhang Y, Venida A, Wang Y, Hughes J, McElwee J, Butrick M, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. 2014;211:2537\u201347.","journal-title":"J Exp Med"},{"key":"175_CR41","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985\u20138.","journal-title":"Science"},{"issue":"12","key":"175_CR42","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3746","volume":"20","author":"D Schubert","year":"2014","unstructured":"Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410\u20136.","journal-title":"Nat Med"},{"key":"175_CR43","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.4049\/jimmunol.1402390","volume":"194","author":"VA Pedicord","year":"2015","unstructured":"Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, Allison JP. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T\u00a0cell priming to promote memory formation and metabolic readiness. J Immunol. 2015;194:2089\u201398.","journal-title":"J Immunol."},{"key":"175_CR44","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.aaa1663","volume":"349","author":"B Lo","year":"2015","unstructured":"Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. Autoimmune disease: patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349:436\u201340.","journal-title":"Science"},{"key":"175_CR45","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2141.2005.05496.x","volume":"129","author":"VK Rao","year":"2005","unstructured":"Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005;129:534\u20138.","journal-title":"Br J Haematol"},{"key":"175_CR46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/bjh.13533","volume":"171","author":"M Miano","year":"2015","unstructured":"Miano M, Scalzone M, Perri K, Palmisani E, Caviglia I, Micalizzi C, et al. Mycophenolate mofetil and sirolimus as second or further line treatment in children with chronic refractory primitive or secondary autoimmune cytopenias: a single centre experience. Br J Haematol. 2015;171:247\u201353.","journal-title":"Br J Haematol"},{"key":"175_CR47","doi-asserted-by":"publisher","first-page":"15113","DOI":"10.1073\/pnas.2436348100","volume":"100","author":"VI Brown","year":"2003","unstructured":"Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R, et al. Rapamycin is active against B-precursor leukemia in\u00a0vitro and in\u00a0vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci. 2003;100:15113\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"175_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1365-2249.2002.01777.x","volume":"128","author":"G Strauss","year":"2002","unstructured":"Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T\u00a0cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128:255\u201366.","journal-title":"Clin Exp Immunol"},{"key":"175_CR49","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2006-01-010124","volume":"108","author":"DT Teachey","year":"2006","unstructured":"Teachey DT, Obzut DA, Axsom K, Choi JK, Goldsmith KC, Hall J, Hulitt J, Manno CS, Maris JM, Rhodin N, Sullivan KE, Brown VI, Grupp SA. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. 2006;108:1965\u201371.","journal-title":"Blood"},{"key":"175_CR50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2141.2009.07595.x","volume":"145","author":"DT Teachey","year":"2009","unstructured":"Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145:101\u20136.","journal-title":"Br J Haematol"},{"key":"175_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","volume":"127","author":"KL Bride","year":"2016","unstructured":"Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, et al. Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127:17\u201328.","journal-title":"Blood"},{"key":"175_CR52","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/pbc.21264","volume":"50","author":"A Rao","year":"2008","unstructured":"Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50:822\u20135.","journal-title":"Pediatr Blood Cancer."},{"key":"175_CR53","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1182\/blood-2011-04-347641","volume":"118","author":"B Neven","year":"2011","unstructured":"Neven B, Magerus-Chatinet A, Florkin B, Gobert D, Lambotte O, De Somer L, et al. A survey of 90 patients with auto-immune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011;118:4798\u2013807.","journal-title":"Blood"},{"key":"175_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2141.2002.03357.x","volume":"117","author":"J van der Werff Ten Bosch","year":"2002","unstructured":"van der Werff Ten Bosch J, Schotte P, Ferster A, Azzi N, Boehler T, Laurey G, et al. Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations. Br J Haematol. 2002;117:176\u201388.","journal-title":"Br J Haematol."},{"key":"175_CR55","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/ajh.21007","volume":"82","author":"VK Rao","year":"2007","unstructured":"Rao VK, Dowdell KC, Dale JK, Dugan F, Pesnicak L, Bi LL, et al. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL\/lpr\u2212\/\u2212 mice or in patients with autoimmune lymphoproliferative syndrome. Am J Hematol. 2007;82:1049\u201355.","journal-title":"Am J Hematol."},{"key":"175_CR56","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/blood-2013-07-518167","volume":"123","author":"E Boggio","year":"2014","unstructured":"Boggio E, Clemente N, Mondino A, Cappellano G, Oriellieri E, Gigliotti CL, et al. IL-17 protects T\u00a0cells from apoptosis and contributes to development of ALPS-like phenotypes. Blood. 2014;123:1178\u201386.","journal-title":"Blood"},{"key":"175_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ajh.20523","volume":"81","author":"VK Rao","year":"2006","unstructured":"Rao VK, Carrasquillo JA, Dale JK, Bacharach SL, Whatley M, Dugan F, et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). Am J Hematol. 2006;81:81\u20135.","journal-title":"Am J Hematol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0175-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-016-0175-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0175-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0175-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T23:10:41Z","timestamp":1589670641000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-016-0175-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,30]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1007\/s40272-016-0175-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,30]]},"assertion":[{"value":"30 April 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No commercial funding was provided for writing this article. Lindsey A. George and David T. Teachey have no conflicts of interest that are directly relevant to the content of the article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}]}}